Noxopharm progresses US regulatory strategy
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Noxopharm Ltd. is progressing its US regulatory strategy for the SOF-SKN drug candidate, preparing for a pre-Investigational New Drug meeting with the FDA. The company has engaged a global clinical research organization to assist in developing a data package for this meeting. Securing a successful IND application is expected to enhance SOF-SKN's commercial potential and attract industry partners. SOF-SKN is being developed for chronic inflammation caused by autoimmune diseases, with potential applications in other conditions as well.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- New data shows SOF-SKN active ingredient efficacy
- Innovative collaboration further expands Sofra platform
- March 2026 Quarterly Activities Report and Appendix 4C
- Positive SOF-SKN dosing data shows prolonged skin retention
- Noxopharm appoints Dr Olivier Laczka as new CEO
Later from Noxopharm
- Noxopharms Sofra assets to be presented at global conference
- New data confirms cancer-fighting potential
- SOF-SKN manufacturing begins to ensure clinical trial readi
- Quarterly Activities/Appendix 4C Cash Flow Report
- New preclinical data supports immuno-oncology approach
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm